Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis.
The objective of this study was to assess protein levels for candidate cytokines, chemokines, growth factors, matrix metalloproteinases and their inhibitors in bronchoalveolar lavage fluid (BALF) in patients with polar forms of pulmonary sarcoidosis, i.e. Löfgren's syndrome (LS) and more advanced chest X-ray (CXR) stage III disease. Twenty-four inflammatory molecules were analysed in unconcentrated BALF samples from 10 sarcoidosis patients with CXR stage III and 10 patients with LS by semiquantitative protein array. Four novel molecules [CC chemokine ligand (CCL)15, CCL16, macrophage migration inhibitory factor (MIF) and macrophage stimulating protein (MSP)], detected for the first time in association with sarcoidosis, were then quantified by enzyme-linked immunosorbent assay in a second cohort of 68 sarcoidosis patients and 17 control subjects. The protein levels of CCL15, CCL16, CCL24, CXCL8, CXCL9, CXCL10, interleukin-16, MIF, MSP and matrix metallopeptidase 1 were increased in CXR stage III patients when compared with patients with LS. CCL15 and MSP up-regulation in CXR stage III patients in comparison with LS patients and controls was confirmed by enzyme-linked immunosorbent assay. Moreover, MSP was associated with treatment requirement (P = 0.001) and CCL15 was elevated in patients with disease progression at 2-year follow-up (P = 0.016). CCL16 levels were increased in sarcoidosis versus controls (P < 0.05), but no difference was observed between patient subgroups. MIF up-regulation was not confirmed in a larger patient group. In conclusion, chemokines CCL15, CCL16 and MSP were found elevated for the first time in BALF from sarcoidosis patients; our results showed that CCL15 and MSP may affect disease course.
Arakelyan
A
A
Laboratory of Immunogenomics, Palacky University, Olomouc, Czech Republic.
Kriegova
E
E
Kubistova
Z
Z
Mrazek
F
F
Kverka
M
M
du Bois
R M
RM
Kolek
V
V
Petrek
M
M
D000328:Adult; D000704:Analysis of Variance; D015415:Biomarkers / Q000032:analysis; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D016022:Case-Control Studies; D019742:Chemokines, CC / Q000032:analysis*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D017228:Hepatocyte Growth Factor / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation; D019746:Intramolecular Oxidoreductases / Q000032:analysis; D019402:Macrophage Inflammatory Proteins / Q000032:analysis*; D008263:Macrophage Migration-Inhibitory Factors / Q000032:analysis; D008297:Male; D020782:Matrix Metalloproteinases / Q000032:analysis; D008875:Middle Aged; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D017565:Sarcoidosis, Pulmonary / Q000276:immunology*; D015854:Up-Regulation; D055815:Young Adult
D015415:Biomarkers; C108814:CCL15 protein, human; C481939:CCL16 protein, human; D019742:Chemokines, CC; D019402:Macrophage Inflammatory Proteins; D008263:Macrophage Migration-Inhibitory Factors; D011518:Proto-Oncogene Proteins; C082332:macrophage stimulating protein; D017228:Hepatocyte Growth Factor; D020782:Matrix Metalloproteinases; D019746:Intramolecular Oxidoreductases; C515598:MIF protein, human